In addition, discrepancies in study outcomes and adverse event profiles underscore the need for further research to elucidate the efficacy and optimal use of GLP-1 RAs in reducing alcohol consumption in individuals with AUD, obesity, and liver disease. Here, GLP1R is linked to Obesity.